Yahoo Finance 
Antibody Drug Conjugates Market CAGR predicted at 15.4% by 2031: Visiongain Research Inc.
Visiongain has published a new report on Global Antibody Drug Conjugates Market Report Forecast 2021-2031. Forecasts : By Technology (Cleavable Linkers, Non-Cleavable Linkers, Other Technology), By Payload Type (, MMAE, DM4, Camptothecin, DM1, MMAF, Other Payload Type), By Target Antigen ( CD30, HER2, CD22, CD33), By Drug Type (, Adcetris, Kadcyla, Other Drugs), By Application ( Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Application), , By Linker Type (, VC, VA, SMCC, Hydrazone, Other Linker Type) PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) Profiles of Leading Companies, Region and Country.
Visiongain’s analyst says: ‘The Global market for Antibody Drug Conjugates would be around $3.2 billion in 2020 and is projected to grow at a CAGR of 15.1% during the forecast period 2021-2031. The market is estimated to grow at a CAGR of 14.8% in the first half period 2021-2026 and is projected to grow at CAGR of 15.4% in the other half period 2026-2031’.
Download Exclusive Sample of Report @ https://www.visiongain.com/report/antibody-drug-conjugates-market-2021/#download_sampe_div
Key Questions Answered in the report
What are the best investment options for venturing into new product and service lines?
What value proposals should businesses aim at while providing new funding for research and development?
Which regulations will be most useful for stakeholders to enhance their supply chain network?
Which regions could see demand ripening in certain segments in the near future?
What are some of the best cost optimization strategies with vendors that some well-trained players have been successful with?
What are the key perspectives that C-suite is leveraging to move businesses to a new growth trajectory?
Which government regulations could call into question the status of key regional markets?
How will the emerging political and economic scenario affect opportunities in key areas of growth?
What are some of the value-added opportunities in different segments?
What will be the barriers to entry for new players on the market?
Antibody drug conjugate (ADC) technology continues to evolve as a widely successful drug targeting technology for the treatment of cancer. Enormous progress has been made by researchers in the development of ADC constituents. Advances in targeting antibodies, potent payloads and drug-linker technologies that facilitate improved ADC stability, potency and targeting efficiency led to the development of ten commercially viable ADCs. ADCs are the next-generation treatment for various kinds of cancers. With two approved products and many in clinical trials, ADC development has become one of the most attractive classes of biologics.
Increase in Number of Cancer Patients in the World is Creating Opportunities for Cancer Diagnostic Companies
Oncotic, with spending over US$ 100 trillion in major developed and pharmaceutical markets, is the leading class in specialty medicines by 2020. Of the $298 billion growth of developing-market brands by 2020, $135 billion are the product of new medicines, with the largest proportion coming from oncology medicinal products launched over the next five years. These treatments often take years to reach patients outside the main developed markets, which means that the range of innovations will be less widespread in the next five years. The new medicines available are increasingly being used to treat oncology and orphan conditions and to offer a range of specialty molecular medicines.
Other Factors Boosting the Market Growth
Use of known or approved antibodies and cytotoxins in ADCs means potentially streamlined reviews and briefer development cycles.
Technological advances, including stable linker technologies, have provided the impetus to develop more targeted and efficacious ADCs.
Development of more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have an improved safety/efficacy profile.
Increasing incidence of cancer is also contributing to the development of ADCs.
Get Detailed TOC @ https://www.visiongain.com/report/antibody-drug-conjugates-market-2021/#download_sampe_div
Is Complexity of ADCs hindering its Growth?
Manufacturing an ADC is a complex process. It requires a small molecule, an antibody, chemical linking chemistry and different amino acid conjugation. Antibody drug conjugates exhibit a more complex and heterogeneous structure than the parent monoclonal antibody. This complexity and heterogeneity present a significant challenge for generic manufacturers to copy the ADCs; thus, the complexity of ADCs preserves companies’ investment longer.
Leading companies and the potential for market growth
AbbVie Inc.
Astellas Pharma Inc
Bayer Pharmaceuticals
Celldex Therapeutics, Inc.
Genentech Biotechnology
ImmunoGen Biotechnology
Immunomedics Inc
Lonza Group AG (Lonza)
Mersana Therapeutics Inc.
Takeda Pharmaceutical Company Limited
Roche Holding AG (Roche)
Pfizer Inc. (Pfizer)
Lantheus Holdings, Inc.
Seattle Genetics, Inc.
Merck KGaA
Overall world revenue for Antibody Drug Conjugates Market will surpass $3.2 billion in 2020, our work calculates. We predict strong revenue growth through to 2031.
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
The comprehensive report offers market estimation and forecast for the period ranging 2021 – 2031 for leading national markets and rest of the world. Moreover, the report contains dedicated leading companies covering 10 leading producers in the field of Antibody Drug Conjugates.
The Antibody Drug Conjugates Market Report will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the industry.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email contactus@visiongain.com
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Antibody Drug Conjugates Market and leading companies. You will find data, trends and predictions.
Find more research reports on the Pharma Industry click on:
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
About Visiongain
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.
Contact:
Sara Peerun
Commercial Director
Visiongain Inc.
Tel: + 44 207 549 9987
USA Tel: 00 1 718 682 4567
EU Tel: 00 353 1 695 0006
Email: sara.peerun@visiongain.com
Web: https://www.visiongain.com/
Follow Us: LinkedIn | Twitter
-
SOURCE Visiongain Limited.
